Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

What happened

Monopar Therapeutics announced that two abstracts on its investigational Wilson disease treatment ALXN1840 will be presented at the AASLD liver meeting in Denver, Nov. 5–9, 2026. One covers baseline disease burden in the Phase 3 FoCus trial; the other concerns molybdenum balance in treated patients.

Confirmed

Global impact / market context

The presentations may help clinicians and investors assess the drug’s development, but the article reports no results or evidence of improved outcomes. Future findings about benefit or risk could affect the case for continued trials, the company’s development spending, and expectations for potential revenue.

Analyst inference

Monopar describes ALXN1840 as investigational, meaning it is still being developed and is not presented as a marketed treatment. The FoCus abstract concerns patients’ disease burden at baseline, while the second addresses molybdenum balance; neither abstract’s findings are included in the article.

Analyst inference

What to watch

1. Watch for the scheduled oral presentation and companion e-poster on FoCus baseline disease burden at the AASLD meeting, taking place Nov. 5–9, 2026. Confirmed
2. Look for the poster’s findings on molybdenum balance in patients treated with ALXN1840; the article confirms the presentation but does not provide its results. Confirmed
3. Assess whether later disclosures offer evidence about clinical benefit or safety; supportive findings could strengthen the case for continued development, while concerns could raise costs or delay progress. Analyst inference

Evidence

• globenewswire.com